Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner 21 de October de 2026 by
Extracorporeal photopheresis for cancer immunotherapy-related gastrointestinal toxicity: emerging clinical evidence 21 de October de 2026 by Mandal, S., Maji, M., Dhali, A.
Neuroimmune crosstalk in cancer: emerging immunotherapeutic opportunities 21 de October de 2026 by Dong, T., Ploeger, H., Eichwald, T., Brabenec, L., Rafei, M., Amit, M., Gargano, A., Talbot, S.
Observation versus maintenance immunotherapy after PD-1-induced clinical complete response in dMMR/MSI-H colorectal cancer managed non-operatively: a multicenter cohort study 20 de October de 2026 by
Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy 20 de October de 2026 by Wei, C., Fu, Q., Wei, H., Zhai, H., Dong, S., Ma, X., Bie, L., Ma, Y., Wang, Y., Xia, Q., Luo, S., Li, N.
PCSK9 drives acquired resistance to anti-PD-1 immunotherapy through cystine metabolic reprogramming in lung cancer 20 de October de 2026 by Jie, G., Cao, Z., Wang, J., Lu, W., Zhu, X., Li, Z., Wang, Y., Lu, S., Xia, L.
HER2 CAR-expressing iPSC-derived iNKT cells exhibit multifaceted immunomodulatory functions beyond direct tumor killing 20 de October de 2026 by
Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01 19 de October de 2026 by
Distinct genomic landscapes of mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancer depending on tumor mutation burden (TMB) levels 15 de October de 2026 by
Temporal and therapeutic confounders in predicting efficacy of immunotherapy rechallenge via baseline intratumoral tertiary lymphoid structures 15 de October de 2026 by Sun, A., Chen, H., Wei, A.
